Latest BioInvent News & Updates

See the latest news and media coverage for BioInvent. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioInvent

Clinical-stage biopharmaceutical company developing cancer immunotherapies

bioinvent.com

Headquarters: Lund, Sweden
Company type: Public company
Number of employees: 125–200

Last updated Today

Latest news about BioInvent

In short: BioInvent reported significant clinical success for its lead antibodies BI-1206 and BI-1808, achieving high response rates in NHL and CTCL trials.

Company announcements

June 16 BioInvent

BioInvent presents promising clinical data at EHA2026

BI-1206 showed 81% response rate in follicular lymphoma, and BI-1808 achieved 40% ORR in CTCL.

June 11 BioInvent

BioInvent's BI-1206 triplet achieves 83% response rate in refractory NHL

The combination showed 81% ORR in follicular lymphoma and lower serious adverse events (14%) versus SOC regimens.

June 11 BioInvent

BioInvent announces positive clinical data for BI-1808 in CTCL

40% ORR as monotherapy and 50% in combination with pembrolizumab, with immune activation confirmed.

May 21 BioInvent

BioInvent announces promising clinical data for combination therapy

BI-1808 plus KEYTRUDA showed 24% ORR and 56% DCR in heavily pretreated ovarian cancer patients.

Media coverage

June 13 The Globe and Mail

BioInvent to Showcase New BI-1206 and BI-1808 Hematology Data at Stockholm KOL Event

Detailed price information for Bioinvent International Ab (BOVNF) from The Globe and Mail including charting and trades.

June 11 The Globe and Mail

BioInvent’s BI-1206 Triplet Delivers Strong Efficacy and Safety in Refractory NHL

Detailed price information for Bioinvent International Ab (BOVNF) from The Globe and Mail including charting and trades.

June 11 Yahoo Finance

BioInvent's TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA ...

Selectively targeting TNFR2 to deplete Tregs and reactivate anti-tumor immunity, BI-1808 holds FDA Fast Track and Orphan Drug designations in CTCL. LUND, SE / ACCESS...

May 20 Dagens industri

"Very promising" phase 2 study for Bioinvent

Bioinvent announces early data from its ongoing phase 2a study evaluating BI-1808, a monoclonal antibody targeting TNFR2, in combination with...

Never miss news about BioInvent

Track BioInvent and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioInvent competitors & trending companies

Browse news for competitors to BioInvent and other trending companies.